UY30338A1 - Acidos carboxilicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos. - Google Patents

Acidos carboxilicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos.

Info

Publication number
UY30338A1
UY30338A1 UY30338A UY30338A UY30338A1 UY 30338 A1 UY30338 A1 UY 30338A1 UY 30338 A UY30338 A UY 30338A UY 30338 A UY30338 A UY 30338A UY 30338 A1 UY30338 A1 UY 30338A1
Authority
UY
Uruguay
Prior art keywords
preparation
phenylaminobenzoxazol
procedures
pharmaceutical products
acids replaced
Prior art date
Application number
UY30338A
Other languages
English (en)
Inventor
Dr Stefan Bartoschek
Dr Guido Haschke
Dr-Viktoria Drosou
Dr Markus Follmann
Dr Gerhard Hessler
Dr Siegfried Stengelin
Dr Andreas Herling
Dr Thomas Klabunde
Dr Elisabeth Defossa
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UY30338A1 publication Critical patent/UY30338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Acidos carboxílicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos La invencion se refiere a ácidos carboxílicos sustituidos con fenilaminobenzoxazol y a sus sales fisiologicamente toleradas. La invencion se refiere a compuestos de la formula I en la que R1, R2, R6, R7, R8, R9, R10, m y X tienen los significados establecidos, y a sus sales fisiologicamente toleradas. Los compuestos son adecuados para el tratamiento de la diabetes.
UY30338A 2006-05-11 2007-05-10 Acidos carboxilicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos. UY30338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
UY30338A1 true UY30338A1 (es) 2008-01-02

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30338A UY30338A1 (es) 2006-05-11 2007-05-10 Acidos carboxilicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos.

Country Status (31)

Country Link
US (2) US20090149519A1 (es)
EP (1) EP2024347B1 (es)
JP (1) JP2009536629A (es)
KR (1) KR20090006846A (es)
CN (1) CN101437805B (es)
AR (1) AR060990A1 (es)
AU (1) AU2007250213B2 (es)
BR (1) BRPI0711448A2 (es)
CA (1) CA2651660A1 (es)
CO (1) CO6241107A2 (es)
CY (1) CY1113177T1 (es)
DE (1) DE102006021878A1 (es)
DK (1) DK2024347T3 (es)
ES (1) ES2391203T3 (es)
HK (1) HK1131978A1 (es)
HR (1) HRP20120829T1 (es)
IL (1) IL195179A0 (es)
MA (1) MA30402B1 (es)
MX (1) MX2008014102A (es)
MY (1) MY148258A (es)
NO (1) NO20085068L (es)
NZ (1) NZ572692A (es)
PL (1) PL2024347T3 (es)
PT (1) PT2024347E (es)
RS (1) RS52450B (es)
RU (1) RU2434003C2 (es)
SI (1) SI2024347T1 (es)
TW (1) TW200812987A (es)
UY (1) UY30338A1 (es)
WO (1) WO2007131622A1 (es)
ZA (1) ZA200808490B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
JP2010524932A (ja) 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸ｇｐｒ４０調節物質
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
WO2009145829A1 (en) * 2008-04-01 2009-12-03 University Of Massachusetts Type iii secretion inhibitors, analogs and uses thereof
CA2716352C (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201317229A (zh) * 2011-09-14 2013-05-01 Daiichi Sankyo Co Ltd 稠合雜環衍生物
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
PE20210640A1 (es) 2018-02-13 2021-03-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
ES2962674T3 (es) 2018-07-13 2024-03-20 Gilead Sciences Inc Inhibidores PD-1/PD-L1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
KR20210123321A (ko) 2019-01-11 2021-10-13 내기스 파마슈티컬스 인코포레이티드 류코트리엔 합성 억제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491863A (en) * 1973-10-23 1977-11-16 Lilly Industries Ltd 2,5-or 2,6-disubstituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
ATE188379T1 (de) * 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
DK0966465T3 (da) * 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
AU5052199A (en) * 1998-07-23 2000-02-14 Astrazeneca Ab Chemical compounds
DK1153017T3 (da) * 1999-02-16 2006-07-17 Aventis Pharma Ltd Bicykliske forbindelser og deres anvendelse som integrinreceptorligander
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
EP1330432A2 (en) * 2000-11-04 2003-07-30 Aventis Pharma Limited Substituted alkanoic acids
EP1346982B1 (en) * 2000-12-28 2011-09-14 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Also Published As

Publication number Publication date
TW200812987A (en) 2008-03-16
MX2008014102A (es) 2008-11-14
DE102006021878A1 (de) 2007-11-15
KR20090006846A (ko) 2009-01-15
AU2007250213B2 (en) 2013-04-11
CN101437805A (zh) 2009-05-20
NZ572692A (en) 2011-03-31
SI2024347T1 (sl) 2012-11-30
CO6241107A2 (es) 2011-01-20
HK1131978A1 (en) 2010-02-12
JP2009536629A (ja) 2009-10-15
US20090149519A1 (en) 2009-06-11
ZA200808490B (en) 2009-10-28
NO20085068L (no) 2009-02-04
MY148258A (en) 2013-03-29
CN101437805B (zh) 2012-05-30
PT2024347E (pt) 2012-10-09
IL195179A0 (en) 2009-08-03
RU2434003C2 (ru) 2011-11-20
EP2024347A1 (de) 2009-02-18
RS52450B (en) 2013-02-28
ES2391203T3 (es) 2012-11-22
DK2024347T3 (da) 2012-10-29
AR060990A1 (es) 2008-07-30
CA2651660A1 (en) 2007-11-22
RU2008148838A (ru) 2010-06-20
EP2024347B1 (de) 2012-08-01
AU2007250213A1 (en) 2007-11-22
CY1113177T1 (el) 2016-04-13
PL2024347T3 (pl) 2013-01-31
WO2007131622A1 (de) 2007-11-22
BRPI0711448A2 (pt) 2011-11-08
MA30402B1 (fr) 2009-05-04
US20130303578A1 (en) 2013-11-14
HRP20120829T1 (hr) 2012-11-30
US8748465B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
UY30338A1 (es) Acidos carboxilicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos.
UY30337A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo, procedimientos para su preparacion y su uso como productos farmacéuticos.
UY30339A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para su preparacion y su uso como productos farmacéuticos
UY31350A1 (es) (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1119200T1 (el) Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες
DOP2010000242A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
UY33483A (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento.
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
UY32848A (es) Compuestos heterocíclicos de oxima
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31968A (es) Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
GT200600463A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
UY32605A (es) Agentes antiinflamatorios como compuestos virostáticos
UY33200A (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CR20110219A (es) Ácidos naftilacéticos
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.
UY33655A (es) Co-cristales y sales de inhibidores de ccr30

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170906